| front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31|32 |33 |34 |35 |36 |37 |38 |39 |40 |41 |42 |43 |44 |45 |46 |47 |48 |49 |50 |51 |52 |53 |54 |55 |56 |57 |58 |59 |60 |61 |62 |review |
|
The
eligibility criteria are seen here and it should be noted that there were
two cohorts. One was designed to look at the incidence of any complications,
particularly retinopathy, that is the primary cohort, and another to examine
the effect of glycemic control on the early progression of complications,
the secondary cohort. |